CODX Stock Risk & Deep Value Analysis
Co-Diagnostics Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About CODX Stock
We analyzed Co-Diagnostics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CODX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CODX Risk Analysis & Red Flags
What Could Go Wrong
The company is burning substantial cash with annual revenue of only $0.6M and a mere $11.9M in cash on hand. Without immediate and significant revenue generation from its new platform, further dilutive capital raises are highly probable, which could severely depress the stock price and extend the path to profitability indefinitely.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
84.6% YoY revenue decline in FY2025
- ⚠
60% reduction in cash and marketable securities (YoY to $11.9M)
- ⚠
Increased net loss of $46.9M, including $18.9M impairment charge
- ⚠
High P/S ratio (6.4x) on rapidly declining revenue, indicating market is valuing speculative future growth
- ⚠
History of share dilution mentioned in previous analysis, likely to continue given cash burn
Upcoming Risk Events
- 📅
Failure of Co-Dx PCR platform to gain market traction or secure significant orders
- 📅
Further accelerated cash burn requiring highly dilutive capital raises
- 📅
Intensified competition in molecular diagnostics leading to price compression
- 📅
Negative regulatory developments or delays in product approvals
When to Reconsider
- 🚪
Quarterly revenue fails to show any sequential recovery for two consecutive quarters
- 🚪
Cash and marketable securities fall below $5 million without a clear funding plan
- 🚪
Announcement of a highly dilutive capital raise (>20% share increase)
- 🚪
Major competitive product launch that directly threatens the Co-Dx PCR platform
Unlock CODX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Co-Diagnostics Inc (CODX) Do?
Market Cap
$5.12M
Sector
Healthcare
Industry
Medical Devices
Employees
132
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Visit Co-Diagnostics Inc WebsiteInvestment Thesis
Co-Diagnostics is a deep value, high-risk turnaround play attempting to leverage its proprietary Co-Dx PCR platform to re-establish itself in the molecular diagnostics market, particularly focusing on emerging opportunities like TB diagnostics in South Asia. Success hinges on immediate and aggressive commercialization that reverses the current revenue decline and cash burn, validating its strategic pivot and competitive advantages to achieve significant market share and profitability within 3-5 years.
Is CODX Stock Undervalued?
Unlock the full AI analysis for CODX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CODX Price Targets & Strategy
12-Month Target
$2.80
Bull Case
$14.20
Bear Case
$0.50
Valuation Basis
Implied 7x forward P/S on projected FY26 revenue of $2.5M (modest recovery post-pivot) = ~$17.5M MC, or ~$2.48/share, rounded to $2.80 to account for market sentiment swing potential.
Entry Strategy
Given high volatility, dollar-cost average into any sustained dips below $1.50, seeking to enter near recent support zones or periods of positive news related to commercialization efforts.
Exit Strategy
Consider profit-taking for 25-50% of position if the stock approaches $5-$6 (initial pivot validation). Place a stop-loss order if the stock drops below $1.00 on sustained negative news or accelerated cash burn.
Portfolio Allocation
1-2% for aggressive risk tolerance only, as this is a high-risk turnaround play.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CODX Financially Healthy?
Profitability
Gross Margin
64.27%
Operating Margin
-7929.36%
Net Margin
-7533.61%
Return on Equity
-125.46%
Revenue Growth
-84.10%
EPS
$-32.39
Balance Sheet
Current Ratio
3.87
Quick Ratio
3.42
Cash & Equivalents
$11.90M
Cash Flow
EBITDA
-$28.00M
Other
Beta (Volatility)
1.30
Does CODX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding (The company's historical revenue streams are collapsing, and while they are trying to build a new moat around their Co-Dx platform, it is not yet proven or generating meaningful revenue.)
Moat Sources
1 Identified
Highly uncertain. The durability of any potential moat is dependent on the unique efficacy and cost-effectiveness of the Co-Dx PCR platform, its successful regulatory approval and market adoption, and its ability to withstand competition from larger, well-funded diagnostic giants with established distribution networks.
Moat Erosion Risks
- •Competitors developing superior or cheaper molecular diagnostic technologies
- •Slow adoption rates for the Co-Dx PCR platform in target markets
- •Inability to scale manufacturing and distribution effectively
- •Regulatory hurdles or changes that favor incumbent technologies
CODX Competitive Moat Analysis
Sign up to see competitive advantages
CODX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Slightly Bullish (Despite earnings miss, stock surged 12.12% post-announcement, indicating some underlying optimism or speculative interest among retail traders.)
Institutional Sentiment
Neutral (No analyst consensus, price targets, or upgrades/downgrades provided in recent intelligence. Lack of institutional coverage signals low interest or high uncertainty.)
Insider Activity (Form 4)
No Form 4 filings or insider trading activity data available in search results provided.
Options Flow
Normal options activity (No specific unusual options activity data provided in search results.)
Earnings Intelligence
Next Earnings
Estimated mid-May 2026 for Q1 2026 results
Surprise Probability
Medium (Recent earnings were a revenue miss, yet the stock surged, making future reactions unpredictable based on headline numbers alone.)
Historical Earnings Pattern
The stock recently surged 12.12% post-Q4 2025 earnings despite a revenue miss and increased net loss, suggesting market attention may be on strategic pivots, future outlook, or adjusted non-GAAP figures rather than immediate GAAP profitability.
Key Metrics to Watch
Competitive Position
Top Competitor
Abbott (ABT)
Market Share Trend
Losing/Minimal (Given the substantial revenue decline and pivot, current market share is likely minimal and declining in traditional segments, while aiming to gain share in new, specific niches.)
Valuation vs Peers
CODX is unprofitable with extremely low revenue, making direct P/E or EV/EBITDA comparisons difficult. Its P/S of 6.4x on declining revenue is high, suggesting the market is assigning a significant speculative value to its future growth potential, which is typically seen in high-growth companies, not those with an 84.6% revenue drop. Established peers like Abbott trade on much more stable, albeit lower, multiples on a much larger revenue base.
Competitive Advantages
- •Proprietary Co-Dx PCR platform technology with potential for high accuracy and scalability
- •Strategic focus on specific high-growth niche areas like TB diagnostics
- •Established CoSara JV in the significant South Asia market
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CODX Stock Higher?
Near-Term (0-6 months)
- •ESCMID 2026 Conference (April 17-21, 2026) - potential for international commercial relationship announcements
- •Q1 2026 Earnings (Estimated mid-May 2026) - focus on commentary regarding commercialization progress
Medium-Term (6-18 months)
- •First substantial revenue contributions from Co-Dx PCR platform commercialization (Q3/Q4 2026)
- •Major partnership or distribution agreement for TB diagnostics in South Asia through CoSara JV
- •Further regulatory approvals or expanded indications for Co-Dx PCR platform
Long-Term (18+ months)
- •Establishment as a niche leader in specific molecular diagnostics segments (e.g., TB testing)
- •Broad adoption of Co-Dx PCR as a preferred platform in emerging markets
- •Attainment of sustainable profitability and positive free cash flow
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CODX?
- ✓
Consistent quarter-over-quarter revenue growth demonstrating traction of new products/markets
- ✓
Material reduction in quarterly cash burn and progress towards positive operating cash flow
- ✓
Announcements of significant commercial partnerships or large-scale adoption contracts
- ✓
Positive regulatory updates or expanded product claims for the Co-Dx PCR platform
Bull Case Analysis
See what could go right with Premium
Competing with CODX
See how Co-Diagnostics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Co-Diagnostics Inc CODX | $5.1M | 3.8 | — | $622,489 | -7533.6% | -84.1% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Co-Diagnostics Inc Makes Money
Co-Diagnostics Inc. is a molecular diagnostics company that develops and manufactures advanced PCR (Polymerase Chain Reaction) testing solutions. The company's business model is currently in a transitional phase, moving away from previous revenue streams, and now primarily focused on the commercialization of its next-generation Co-Dx PCR platform. They aim to generate revenue by selling diagnostic instruments, proprietary reagents, and testing kits, particularly for infectious diseases like tuberculosis, with a strategic emphasis on expanding into new international markets such as South Asia through joint ventures. Success in this pivot would allow them to sell their platform and related consumables directly to laboratories, hospitals, and governments, aiming for a scalable model based on technology adoption.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Co-Diagnostics Inc (CODX)?
As of April 16, 2026, Co-Diagnostics Inc has a DVR Score of 3.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Co-Diagnostics Inc?
Co-Diagnostics Inc's market capitalization is approximately $5.1M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Co-Diagnostics Inc use?
CODX is the ticker symbol for Co-Diagnostics Inc. The company trades on the NCM.
What is the risk level for CODX stock?
Our analysis rates Co-Diagnostics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Co-Diagnostics Inc's revenue growing?
Co-Diagnostics Inc has reported revenue growth of -84.1%. Revenue has been declining, which warrants closer examination.
Is CODX stock profitable?
Co-Diagnostics Inc has a profit margin of -7533.6%. The company is currently unprofitable.
How often is the CODX DVR analysis updated?
Our AI-powered analysis of Co-Diagnostics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CODX (Co-Diagnostics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.